Jul. 11, 2018
Advocacy, Events, Featured News, Industry, Patients & Members, Research
Posted by Lisa Sencen
Dr. Scott Gottlieb was sworn in as the 23rd Commissioner of Food and Drug Administration in 2017, and provided a keynote speech at the NORD Rare Summit shortly thereafter. 2018 marks his second year at the Summit, and we look forward to Dr. Gottlieb’s update for the rare disease community.
In addition to Dr. Gottlieb’s feature as the 2018 keynote speaker, there are plenty of reasons to register for the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit! Here are four additional reasons you shouldn’t miss this opportunity to hear from experts and join the conversation about the new era of patient-focused innovation:
In a special Patient Perspectives Panel, patients and caregivers will share their hopes, questions and concerns about gene therapy and how this potential game-changer is perceived in their communities.
FDA senior staff will share their perspectives on the current status and future outlook for Patient-Focused Drug Development, and the implications for all stakeholders. Also, the division heads of CDER, CBER and CDRH will share insights and predictions for orphan product trends, opportunities and challenges.
From artificial intelligence to facial recognition software, technology offers hope for addressing many rare disease challenges. We’ll explore some of these innovative approaches in an Embracing Innovation to Advance Science track.
In addition to the content that we have packed into the 2018 NORD Rare Summit, attendees will be presented with hundreds of networking opportunities with some of the rare disease community’s top leaders.
Learn more and register here.